The Phase 3 study of Retatrutide (LY3437943) in participants with Type 2 Diabetes Mellitus who have obesity or are overweight reached primary completion on 2026-06-16. This trial, which enrolled 1152 participants, is evaluating the efficacy and safety of the drug for these conditions.
Background
Retatrutide is being investigated for the treatment of Type 2 Diabetes Mellitus in individuals who also have obesity or are overweight. A subset of participants in this study also includes those with obstructive sleep apnea (OSA).
Trial design
The study, identified as NCT05929079, is a Phase 3 clinical trial. It enrolled 1152 participants with Type 2 Diabetes Mellitus who have obesity or are overweight, including a subset with obstructive sleep apnea. The interventions being compared are retatrutide and placebo. The study duration is approximately 89 weeks, involving up to 24 visits.
What this means
The primary completion of this Phase 3 study signifies that all data collection for the trial's primary outcomes has concluded. Researchers will now proceed with data analysis to assess the efficacy and safety profile of retatrutide in the specified participant population. The findings from this large-scale trial will be crucial in determining the potential role of retatrutide in managing Type 2 Diabetes Mellitus alongside obesity or overweight.
Source
This information is based on a trial record update from ClinicalTrials.gov, indicating the primary completion of study NCT05929079 on 2026-06-16. The full details are available on clinicaltrials.gov.